Depacon

OVERDOSE

Overdosage with valproate may result in somnolence, heart
block, and deep coma. Fatalities have been reported; however patients have
recovered from valproate serum concentrations as high as 2120 mcg/mL.

In overdose situations, the fraction of drug not bound to
protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may
result in significant removal of drug. General supportive measures should be
applied with particular attention to the maintenance of adequate urinary
output.

Naloxone has been reported to reverse the CNS depressant
effects of valproate overdosage. Because naloxone could theoretically also
reverse the antiepilepsy effects of valproate, it should be used with caution
in patients with epilepsy.

CONTRAINDICATIONS

Depacon should not be administered to patients with
hepatic disease or significant hepatic dysfunction [see WARNINGS AND PRECAUTIONS].

Depacon is contraindicated in patients known to have
mitochondrial disorders caused by mutations in mitochondrial DNA polymerase
γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years
of age who are suspected of having a POLG-related disorder [see WARNINGS AND PRECAUTIONS].

Depacon is contraindicated in patients with known
hypersensitivity to the drug [see WARNINGS AND
PRECAUTIONS].

Depacon is contraindicated in patients with known urea
cycle disorders [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 3/9/2015
This monograph has been modified to include the generic and brand name in many instances.